CA2451932A1 - Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases - Google Patents

Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases Download PDF

Info

Publication number
CA2451932A1
CA2451932A1 CA002451932A CA2451932A CA2451932A1 CA 2451932 A1 CA2451932 A1 CA 2451932A1 CA 002451932 A CA002451932 A CA 002451932A CA 2451932 A CA2451932 A CA 2451932A CA 2451932 A1 CA2451932 A1 CA 2451932A1
Authority
CA
Canada
Prior art keywords
ny1y2
compound according
alkyl
effective amount
ny3y4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002451932A
Other languages
English (en)
Other versions
CA2451932C (fr
Inventor
Paul J. Cox
Tahir Nadeem Majid
Shelley Amendola
Stephanie Daniele Deprets
Christopher Edlin
Brian Leslie Pedgrift
Frank Halley
Michael Edwards
Bernard Baudoin
Iain Mclay
David Aldous
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2451932A1 publication Critical patent/CA2451932A1/fr
Application granted granted Critical
Publication of CA2451932C publication Critical patent/CA2451932C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention se rapporte à des composés représentés par la formule (I) ainsi qu'à des N-oxydes, des promédicaments, des bioisostères acides, des sels ou solvates pharmaceutiquement acceptables de ces composés, ou des N-oxydes, des promédicaments ou des bioisostères acides de ces sels ou solvates. L'invention se rapporte également à des compositions contenant ces composés ainsi qu'à des procédés de traitement consistant à administrer, à un patient justiciable d'un tel traitement, ces composés et compositions.
CA002451932A 2001-06-23 2002-06-21 Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases Expired - Fee Related CA2451932C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0115393.1 2001-06-23
GBGB0115393.1A GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds
US30167801P 2001-06-28 2001-06-28
US60/301,678 2001-06-28
PCT/GB2002/002835 WO2003000695A1 (fr) 2001-06-23 2002-06-21 Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases

Publications (2)

Publication Number Publication Date
CA2451932A1 true CA2451932A1 (fr) 2003-01-03
CA2451932C CA2451932C (fr) 2009-12-29

Family

ID=9917225

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002451932A Expired - Fee Related CA2451932C (fr) 2001-06-23 2002-06-21 Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases

Country Status (22)

Country Link
EP (1) EP1404676A1 (fr)
JP (1) JP4344607B2 (fr)
CN (1) CN1294135C (fr)
AU (1) AU2002314325B8 (fr)
BR (1) BR0210652A (fr)
CA (1) CA2451932C (fr)
CZ (1) CZ20033443A3 (fr)
EA (1) EA007415B1 (fr)
EC (1) ECSP034922A (fr)
EE (1) EE05432B1 (fr)
GB (1) GB0115393D0 (fr)
HU (1) HUP0400300A3 (fr)
ME (1) MEP19308A (fr)
NZ (1) NZ529766A (fr)
OA (1) OA12632A (fr)
PL (1) PL374096A1 (fr)
RS (1) RS51698B (fr)
SK (1) SK15882003A3 (fr)
TN (1) TNSN03144A1 (fr)
TR (1) TR200302242T2 (fr)
UA (1) UA76760C2 (fr)
WO (1) WO2003000695A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
CN1678321A (zh) 2002-07-29 2005-10-05 里格尔药品股份有限公司 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
JP2007511596A (ja) * 2003-11-17 2007-05-10 ファイザー・プロダクツ・インク 癌の治療において有用なピロロピリミジン化合物
EP1689407A1 (fr) * 2003-11-25 2006-08-16 Pfizer Products Inc. Methode de traitement de l'atherosclerose
EP1763524A1 (fr) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Derives d'indole et leur utilisation en tant qu'inhibiteurs de kinases
FR2876103B1 (fr) * 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
FR2878849B1 (fr) 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
CA2607901C (fr) 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methodes et compositions pour le traitement de maladies osseuses degeneratives comprenant un compose inhibiteur syk 2,4-pyrimidinediamine
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
MY159449A (en) 2005-12-13 2017-01-13 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
TR201903488T4 (tr) 2007-06-13 2019-04-22 Incyte Holdings Corp Janus kinaz inhibitörü (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-siklopentilpropannitril tuzlarının kullanımı.
JP2011509290A (ja) 2008-01-11 2011-03-24 ナトコ ファーマ リミテッド 抗癌剤としてのピラゾロ［３，４‐ｄ］ピリミジン誘導体
PE20110223A1 (es) 2008-06-10 2011-05-07 Abbvie Inc DERIVADOS DE PIRROLO[2,3-e][1,2,4]TRIAZOLO[4,3-a]PIRAZIN, COMO INHIBIDORES DE QUINASA
WO2010135650A1 (fr) 2009-05-22 2010-11-25 Incyte Corporation Dérivés de n-(hétéro)aryl-pyrrolidine de pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines et pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines en tant qu'inhibiteurs de la janus kinase
AR076920A1 (es) 2009-05-22 2011-07-20 Incyte Corp 3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)octano-o heptano--nitrilo como inhibidores de jak
WO2011018894A1 (fr) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Dérivés de pyrrolopyrimidine comme modulateurs des canaux potassium
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
WO2011029043A1 (fr) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Inhibiteurs hétéroaryles de btk
RS56317B1 (sr) 2009-12-01 2017-12-29 Abbvie Inc Nova triciklična jedinjenja
PT3050882T (pt) 2010-03-10 2018-04-16 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
EP2574168B9 (fr) 2010-05-21 2016-10-05 Incyte Holdings Corporation Formulation topique pour inhibiteur de jak
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CA2818545C (fr) 2010-11-19 2019-04-16 Incyte Corporation Pyrrolopyridines et pyrrolopyrimidines a substitution heterocyclique utilisees en tant qu'inhibiteurs des jak
CN102093364B (zh) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
CN103476776B (zh) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
ES2560611T3 (es) 2011-06-20 2016-02-22 Incyte Holdings Corporation Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
EP2838898B1 (fr) 2012-04-20 2017-01-18 Advinus Therapeutics Limited Composés hétéro-bicycliques substitués, compositions et leurs applications médicinales
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
BR112015001545B1 (pt) 2012-07-26 2022-07-05 Glaxo Group Limited Composto, composição farmacêutica, e, uso de um composto
JP6318156B2 (ja) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
BR112015010663B1 (pt) 2012-11-15 2022-12-06 Incyte Holdings Corporation Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
UA121532C2 (uk) 2013-03-06 2020-06-10 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
EP2970268A1 (fr) 2013-03-13 2016-01-20 AbbVie Inc. Inhibiteurs de la kinase cdk9
WO2014160017A1 (fr) 2013-03-13 2014-10-02 Abbvie Inc. Inhibiteurs de pyridine cdk9 kinase
WO2014160028A1 (fr) * 2013-03-14 2014-10-02 Abbvie Inc. Inhibiteurs de pyrrolopyrimidine cdk9 kinase
JP2016514113A (ja) 2013-03-14 2016-05-19 アッヴィ・インコーポレイテッド ピロロ［２，３−ｂ］ピリジンｃｄｋ９キナーゼ阻害剤
TW201444836A (zh) 2013-03-14 2014-12-01 Abbvie Inc 吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑
EP3721873A1 (fr) 2013-08-07 2020-10-14 Incyte Corporation Formes posologiques à libération prolongée pour un inhibiteur jak1
CN104804001B9 (zh) * 2014-01-24 2022-02-08 江苏柯菲平医药股份有限公司 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913993QA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
JP2020510016A (ja) 2017-03-09 2020-04-02 アッヴィ・インコーポレイテッド クローン病及び潰瘍性大腸炎を処置する方法
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EA202091830A1 (ru) 2018-01-30 2020-12-29 Инсайт Корпорейшн Способы и промежуточные соединения для получения ингибитора jak
MA52219A (fr) 2018-03-30 2021-02-17 Incyte Corp Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
FI3860998T3 (fi) 2018-10-05 2024-03-27 Annapurna Bio Inc Yhdisteitä ja koostumuksia apj-reseptorin aktiivisuuteen liittyvien tautitilojen hoitoon
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027199A1 (fr) * 1996-01-23 1997-07-31 Novartis Ag Pyrrolopyrimidines et leurs procedes de preparation
US6413971B1 (en) * 1996-11-27 2002-07-02 Pfizer Inc Fused bicyclic pyrimidine derivatives
TW505646B (en) * 1998-06-19 2002-10-11 Pfizer Prod Inc Pyrrolo [2,3-d] pyrimidine compounds
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
KR20010085822A (ko) * 1998-09-18 2001-09-07 스타르크, 카르크 키나제 억제제로서의 4-아미노피롤로피리미딘
JP4078074B2 (ja) * 1999-12-10 2008-04-23 ファイザー・プロダクツ・インク ピロロ［２，３−ｄ］ピリミジン化合物

Also Published As

Publication number Publication date
NZ529766A (en) 2008-11-28
CN1518552A (zh) 2004-08-04
RS51698B (en) 2011-10-31
JP2005508300A (ja) 2005-03-31
HUP0400300A3 (en) 2010-12-28
EA007415B1 (ru) 2006-10-27
GB0115393D0 (en) 2001-08-15
CA2451932C (fr) 2009-12-29
CN1294135C (zh) 2007-01-10
SK15882003A3 (sk) 2004-07-07
MEP19308A (en) 2010-06-10
CZ20033443A3 (en) 2004-03-17
OA12632A (en) 2006-06-14
TR200302242T2 (tr) 2004-12-21
EE05432B1 (et) 2011-06-15
AU2002314325B2 (en) 2009-01-08
WO2003000695A1 (fr) 2003-01-03
HUP0400300A2 (en) 2007-08-28
JP4344607B2 (ja) 2009-10-14
RS99203A (en) 2006-12-15
AU2002314325B8 (en) 2009-01-29
EA200400073A1 (ru) 2004-08-26
BR0210652A (pt) 2004-08-10
UA76760C2 (uk) 2006-09-15
EP1404676A1 (fr) 2004-04-07
WO2003000695A8 (fr) 2004-03-11
EE200400003A (et) 2004-02-16
ECSP034922A (es) 2004-04-28
PL374096A1 (en) 2005-09-19
TNSN03144A1 (en) 2005-12-23

Similar Documents

Publication Publication Date Title
CA2451932A1 (fr) Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases
JP2023144075A (ja) 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物
JP4405602B2 (ja) ヒストン脱アセチル化酵素阻害剤
HUP0401876A2 (hu) Béta2 adrenerg receptor agonista hatású aril-anilin-származékok, valamint ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
FI935379A0 (fi) Katekoldietrar som fungerar som selektiva PDEIV-inhibitorer
JP2005508300A5 (fr)
JP6380777B2 (ja) ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物
RU2013154412A (ru) Аминопиримидины в качестве ингибиторов syc
CA2565852C (fr) Derives de phenol et de thiophenol 3- ou 4-monosubstitues utiles en tant que ligands h3
CA2395593A1 (fr) Azaindoles
CA2564201A1 (fr) Derives de tetrahydronaphthyridine utilises comme ligands du recepteur h3 de l'histamine
US11066370B2 (en) Kinase inhibitor compounds, compositions, and methods of treating cancer
JP2012500831A (ja) 新規なウレアおよびチオウレア誘導体
PT1805170E (pt) Inibidores de mif
CA3203205A1 (fr) Combinaisons pharmaceutiques d'inhibiteurs de sos1 pour le traitement et/ou la prevention du cancer
AU2010319398A1 (en) Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
NZ515407A (en) 4-Phenyl-pyrimidine derivatives
RU2004139041A (ru) Применение гетероаренкарбоксамидов в качестве дофамин-d3 лигандов для лечения заболеваний центральной нервной системы
CN114805352A (zh) 作为pi3k/mtor抑制剂的吡咯并吡啶取代的稠合喹啉化合物
JP2007508301A5 (fr)
ES2901452T3 (es) Compuesto de pirimidina
JP6870064B2 (ja) ピリミジン化合物の医薬用途
EP3661512A1 (fr) Composés anticancéreux/anti-fibrose
ES2777550T3 (es) Profármaco de roflumilast
JP7466795B2 (ja) Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130621